新型冠状病毒肺炎疫苗分析：类型、思路与应用。
Analysis of COVID-19 vaccines: Types, thoughts, and application.
机构信息
Department of Clinical Laboratory, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Clinical Laboratory, Zhejiang Hospital, Hangzhou, China.
出版信息
J Clin Lab Anal. 2021 Sep;35(9):e23937. doi: 10.1002/jcla.23937. Epub 2021 Aug 15.
Abstract
OBJECTIVE
To deal with COVID-19, various countries have made many efforts, including the research and development of vaccines. The purpose of this manuscript was to summarize the development, application, and problems of COVID-19 vaccines.
METHODS
This article reviewed the existing literature to see the development of the COVID-19 vaccine.
RESULTS
We found that different types of vaccines had their own advantages and disadvantages. At the same time, the side effects of the vaccine, the dose of vaccination, the evaluation of the efficacy, and the application of the vaccine were all things worth studying.
CONCLUSION
The successful development of the COVID-19 vaccine concerns almost all countries and people in the world. We must do an excellent job of researching the immunogenicity and immune reactivity of the vaccines. We hope this review can help colleagues at home and abroad.
摘要
目的
应对 COVID-19，各国做出了诸多努力，包括疫苗的研发。本文旨在总结 COVID-19 疫苗的研发、应用和问题。
方法
本文通过查阅现有文献，了解 COVID-19 疫苗的发展情况。
结果
我们发现不同类型的疫苗各有优缺点。同时，疫苗的副作用、接种剂量、疗效评估以及疫苗的应用都是值得研究的内容。
结论
COVID-19 疫苗的成功研发关系到世界上几乎所有的国家和人民，我们必须做好疫苗免疫原性和免疫反应性的研究工作。希望本综述能为国内外同行提供帮助。
相似文献
1
Analysis of COVID-19 vaccines: Types, thoughts, and application.
J Clin Lab Anal. 2021 Sep;35(9):e23937. doi: 10.1002/jcla.23937. Epub 2021 Aug 15.
2
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.
Front Immunol. 2021 Apr 12;12:669339. doi: 10.3389/fimmu.2021.669339. eCollection 2021.
3
COVID-19: vaccination problems.
Environ Microbiol. 2021 Jun;23(6):2878-2890. doi: 10.1111/1462-2920.15549. Epub 2021 May 14.
4
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.
5
COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.
J Med Virol. 2022 Apr;94(4):1294-1299. doi: 10.1002/jmv.27463. Epub 2021 Nov 30.
6
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
7
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
8
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection 2020.
9
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.
10
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
引用本文的文献
1
COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions.
AIMS Neurosci. 2025 Jun 18;12(2):222-249. doi: 10.3934/Neuroscience.2025013. eCollection 2025.
2
The efficacy of COVID-19 vaccination in cystic fibrosis patients: a systematic review.
BMC Infect Dis. 2025 Mar 13;25(1):358. doi: 10.1186/s12879-025-10736-6.
3
Rhabdomyolysis secondary to COVID-19 infection and vaccination: a review of literature.
Front Med (Lausanne). 2024 Nov 20;11:1460676. doi: 10.3389/fmed.2024.1460676. eCollection 2024.
4
Methodology of comparative studies on the relative effectiveness of COVID-19 vaccines: a systematic review.
Osong Public Health Res Perspect. 2024 Oct;15(5):395-408. doi: 10.24171/j.phrp.2024.0063. Epub 2024 Oct 15.
5
The Ambivalence of Post COVID-19 Vaccination Responses in Humans.
Biomolecules. 2024 Oct 17;14(10):1320. doi: 10.3390/biom14101320.
6
Post-COVID-19 Vaccination Meningitis and Meningoencephalitis: A Systematic Review of Case Series and Case Reports.
Am J Trop Med Hyg. 2024 Oct 22;112(1):30-36. doi: 10.4269/ajtmh.24-0451. Print 2025 Jan 8.
7
Prevalence of menstrual alterations following COVID-19 vaccination: systematic review & meta-analysis.
BMC Womens Health. 2024 Sep 19;24(1):523. doi: 10.1186/s12905-024-03349-9.
8
Vaccination and Therapeutics.
Adv Exp Med Biol. 2024;1457:165-184. doi: 10.1007/978-3-031-61939-7_9.
9
COVID-19: vaccination, therapeutics and a review of the science and public health.
Ann Med Surg (Lond). 2024 Jul 17;86(9):5343-5353. doi: 10.1097/MS9.0000000000002374. eCollection 2024 Sep.
10
Health Status and COVID-19 Epidemiology in an Inland Region of Portugal: A Retrospective Study.
Int J Environ Res Public Health. 2024 Aug 6;21(8):1033. doi: 10.3390/ijerph21081033.
本文引用的文献
1
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.
N Engl J Med. 2021 May 6;384(18):1774-1775. doi: 10.1056/NEJMc2101927. Epub 2021 Mar 23.
2
Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center.
N Engl J Med. 2021 May 20;384(20):1962-1963. doi: 10.1056/NEJMc2102153. Epub 2021 Mar 23.
3
BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.
N Engl J Med. 2021 May 6;384(18):1775-1777. doi: 10.1056/NEJMc2101951. Epub 2021 Mar 23.
4
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Viruses. 2020 Aug 7;12(8):861. doi: 10.3390/v12080861.
5
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
6
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
7
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
8
New understanding of the damage of SARS-CoV-2 infection outside the respiratory system.
Biomed Pharmacother. 2020 Jul;127:110195. doi: 10.1016/j.biopha.2020.110195. Epub 2020 Apr 28.
9
[Comparison of epidemiological and clinical characteristics of SARS, pandemic (H1N1) 2009 and COVID-19, and consideration of the prevention and control strategies on COVID-19].
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Jul 6;54(7):713-719. doi: 10.3760/cma.j.cn112150-20200403-00508.
10
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response.
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):407-412. doi: 10.1016/j.dsx.2020.04.020. Epub 2020 Apr 18.
Zotero 插件